Triple Negative Breast Cancer, "I Won't Back Down!": Komen's Power of the Promise 2019

What is TNBC

WHAT IS TRIPLE NEGATIVE BREAST CANCER?

Just in recent years, Triple Negative Breast Cancer (TNBC) has sparked interest in the news where instead of calling the tumor as ER-negative, PR-negative, and HER2-negative; researchers began using the shorthand term, "Triple Negative," dubbed the "new type" of breast cancer. Being Triple Negative, you don't have a targeted therapy and your only treatment option is chemotherapy.

Triple Negative Breast Cancer is seen in about 15% of all breast cancers. TNBC is a very aggressive cancer that tends to strike younger women, pre-menopause, especially among African-American women and women who have BRCA1 mutations. The tumor tends to be fast growing and is less likely to show up on an annual mammogram. TNBC is more likely to metastasis early on; has a high rate of recurrence in the first 2-3 years from diagnosis and has a poorer prognosis than other types of breast cancer due to lack of specific, targeted treatment for TNBC.

Saturday, April 20, 2019

Komen's Power of the Promise 2019

On April 11, 2019, I attended Komen's Power of the Promise benefit, and was honored to be a guest of Dr. Amit Tiwari at his table of University of Toledo's Triple Negative Breast Cancer researchers.
Dr. Amit Tiwari and his research team were recognized for their Komen funded research on overcoming drug resistance in Triple Negative Breast Cancer. The support of each table of attendees stood up arounds us, clapping their hands got me a little teary-eyed... brought me much hope that is so needed in our breast cancer community.
.